Skip to content

Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years

Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00230893
Enrollment
99
Registered
2005-10-03
Start date
2005-07-31
Completion date
2005-09-30
Last updated
2006-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Traumatic Stress Disorder, PTSD

Keywords

Antipsychotics, PTSD, Post Traumatic Stress Disorder, monotherapy, adjunct therapy

Brief summary

The primary objective is to examine the percentage of patients with PTSD who were prescribed an antipsychotic over the past seven years in the VA Network 7 (AL, GA, SC) and compare the percentage on an annual basis. We will also determine the type and dose of antipsychotics received. We hypothesize that there has been a significant increase in antipsychotic use, especially atypical antipsychotics, prescribed for patients with PTSD over the last 7 years

Detailed description

This study is a retrospective electronic review of the VISN 7 Data Warehouse to determine what have been the emerging trends in prescriptions of atypical antipsychotic medications over the past seven years for the treatment of posttraumatic stress disorder (PTSD) in the VA This study is a retrospective electronic review of patients of the VISN 7 Data Warehouse of patients with a diagnosis of PTSD treated with antipsychotics as monotherapy or adjunctive therapy at a VA Medical Center or VA clinic in VISN 7 (GA, SC, and AL). The data will be retrieved from a computerized list of patients treated in VA VISN 7 for PTSD from 1998-2005 and cross-referenced with the electronic pharmacy file for having received a prescription of an antipsychotic medication. No personal identifiers will be collected. The data will then be examined to determine what type of antipsychotics were prescribed and the dose and duration of the antipsychotics. In addition, demographics and clinical characteristics available through the Data Warehouse will be collected.

Interventions

None listed

Sponsors

Janssen, LP
CollaboratorINDUSTRY
Tuscaloosa Research & Education Advancement Corporation
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female patients, any race or ethnic origin at least 19 years of age. * Patients with a diagnosis of PTSD * Treated with an antipsychotic as a monotherapy or adjunctive therapy * Patient must have been seen at a VA medical center or clinic within VISN 7 during the study period.

Exclusion criteria

* Patients not diagnosed with PTSD * Not treated with an antipsychotic as a monotherapy or adjunctive therapy * Patients outside of Network 7 * Patients with a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026